Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 229,100 shares, a growth of 9.8% from the October 31st total of 208,700 shares. Based on an average trading volume of 127,300 shares, the days-to-cover ratio is presently 1.8 days.
Co-Diagnostics Stock Performance
NASDAQ CODX traded up $0.05 during trading on Monday, hitting $0.94. The stock had a trading volume of 118,069 shares, compared to its average volume of 139,672. Co-Diagnostics has a 12 month low of $0.85 and a 12 month high of $2.23. The company’s 50-day moving average price is $1.18 and its two-hundred day moving average price is $1.24. The company has a market capitalization of $29.93 million, a PE ratio of -0.64 and a beta of -0.84.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “neutral” rating and issued a $1.50 price target on shares of Co-Diagnostics in a research note on Monday, November 11th.
Hedge Funds Weigh In On Co-Diagnostics
An institutional investor recently bought a new position in Co-Diagnostics stock. Koss Olinger Consulting LLC purchased a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned 0.19% of Co-Diagnostics as of its most recent filing with the Securities & Exchange Commission. 14.99% of the stock is currently owned by institutional investors.
About Co-Diagnostics
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
Recommended Stories
- Five stocks we like better than Co-Diagnostics
- 3 REITs to Buy and Hold for the Long Term
- How to Master Trading Discipline: Overcome Emotional Challenges
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.